Q2 2019 Biogaia AB Earnings Call Transcript
Ladies and gentlemen, welcome to BioGaia Q2 report 2019. Today, I'm pleased to present CEO, Isabelle Ducellier. (Operator Instructions)
Speakers, please begin.
()-
Yes, thank you. Good morning, everybody. I hope you had or you are having nice holiday. And today, we are going to speak about the quarter 2 2019 for BioGaia.
So basically, we are very happy to start by saying that the sales of our own product have been increasing by 20%, which are a strong increase, and the total sales of the company for Q2 has increased by 11%. This is driven by both Pediatrics plus 19% and Adult product plus 27%. I will come back to that later. It's driven as well by the good sales on our main product, Protectis drop, but the extremely strong increase of the Protectis tablet by 52%. As for the BioGaia Prodentis lozenges, plus 56%.
In term of regional split, we have a very strong growth in Asia Pacific by 58% followed by Americas plus 25%, and good growth of our own
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
